Human umbilical cord-derived mesenchymal stem cell therapy (Puren Hospital Affiliated to Wuhan University of Science and Technology)

N/A

Report date: 2024/11/22 20:00:28

Base Information

Drug NameHuman umbilical cord-derived mesenchymal stem cell therapy (Puren Hospital Affiliated to Wuhan University of Science and Technology)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Source of cells > Umbilical cord-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy

Mechanisms of ActionStem cell replacements

TargetsNot applicable

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaPending

Originator CompaniesPuren Hospital Affiliated To Wuhan University Of Science And Technology

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPuren Hospital Affiliated To Wuhan University Of Science And Technology

Active IndicationsN/A

Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A